PHARMACOKINETIC-DYNAMIC RELATIONSHIP OF CISPLATIN IN-VITRO - SIMULATION OF AN IV BOLUS AND 3 H AND 20 H INFUSION

被引:39
作者
MA, J
VERWEIJ, J
KOLKER, HJ
VANINGEN, HE
STOTER, G
SCHELLENS, JHM
机构
[1] DR DANIEL DENHOED CLIN,ROTTERDAM CANC INST,DEPT MED ONCOL,EXPTL CHEMOTHERAPY & PHARMACOL LAB,3008 AE ROTTERDAM,NETHERLANDS
[2] DR DANIEL DAN HOED KLIN,ROTTERDAM CANC INST,DEPT CLIN CHEM,3008 AE ROTTERDAM,NETHERLANDS
关键词
D O I
10.1038/bjc.1994.166
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The profiles of an i.v. bolus and 3 h and 20 h infusion of cisplatin (CDDP) were simulated in vitro by using a culture of the IGROV1 human ovarian cancer cell line. Disappearance of pharmacologically active unbound CDDP was accomplished by adding human albumin to the medium. Total and unbound CDDP and CDDP-DNA adduct levels were quantitated by atomic absorption spectroscopy (AAS), and tumour cell survival was measured by the clonogenic assay. The design of the experiment resulted in non-significant differences in the magnitude of the area under the concentration-time curve (AUC) of unbound CDDP between the three dose-input functions (AUC i.v. bolus, 6.34 +/- 0.36; 3 h infusion, 6.35 +/- 0.59; and 20 h infusion, 6.76 +/- 0.40 mu g h ml(-1)). Also, the differences between the area under the CDDP-DNA adduct-time curves (AUA) of the three dose-input functions were not significant. The initial rate of decline of the CDDP-DNA adduct-time curve was significantly higher for the i.v. bolus and 3 h infusion than for the 20 h infusion. There was a log-linear relationship between the AUC of unbound CDDP and cell survival. These relationships were not significantly different between the three dose-input functions. Variation in the rate of input of CDDP leads to differences in the shape of the AUC and AUA without significant effects on cell survival.
引用
收藏
页码:858 / 862
页数:5
相关论文
共 23 条
[11]  
PLOOY ACM, 1984, CANCER RES, V44, P2043
[12]  
REED E, 1990, CANCER RES, V50, P2256
[13]   THE MEASUREMENT OF CISPLATIN DNA ADDUCT LEVELS IN TESTICULAR CANCER-PATIENTS [J].
REED, E ;
OZOLS, RF ;
TARONE, R ;
YUSPA, SH ;
POIRIER, MC .
CARCINOGENESIS, 1988, 9 (10) :1909-1911
[14]  
REED E, 1988, ATOM SPECTROSC, V9, P93
[15]  
SALEM P, 1984, CANCER, V53, P837, DOI 10.1002/1097-0142(19840215)53:4<837::AID-CNCR2820530403>3.0.CO
[16]  
2-L
[17]   DRUG-RELATED CHROMOSOMAL CHANGES IN CHEMORESISTANT HUMAN OVARIAN-CARCINOMA CELLS [J].
TEYSSIER, JR ;
BENARD, J ;
FERRE, D ;
DASILVA, J ;
RENAUD, L .
CANCER GENETICS AND CYTOGENETICS, 1989, 39 (01) :35-43
[18]   EFFECTS OF PROLONGED EXPOSURE TO CISPLATIN ON CYTOTOXICITY AND INTRACELLULAR DRUG CONCENTRATION [J].
TROGER, V ;
FISCHEL, JL ;
FORMENTO, P ;
GIOANNI, J ;
MILANO, G .
EUROPEAN JOURNAL OF CANCER, 1992, 28A (01) :82-86
[19]  
VERMORKEN JB, 1982, EUR J CANCER CLIN ON, V18, P1069, DOI 10.1016/0277-5379(82)90085-2
[20]   PHARMACOKINETICS OF FREE AND TOTAL PLATINUM SPECIES AFTER RAPID AND PROLONGED INFUSIONS OF CISPLATIN [J].
VERMORKEN, JB ;
VANDERVIJGH, WJF ;
KLEIN, I ;
GALL, HE ;
VANGROENINGEN, CJ ;
HART, GAM ;
PINEDO, HM .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 39 (02) :136-144